Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) Posts Earnings Results, Misses Expectations By $0.06 EPS

Key Points

• Fresenius reported Q1 EPS of $0.53 (missed consensus by $0.06) and revenue of $5.34B, but delivered organic revenue +4%, operating income +10% (margin +70 bps to 10.1%), completed an accelerated EUR 1bn share buyback, and raised FY‑2026 revenue guidance above street, which lifted the stock.
• Near‑term headwinds include pressured U.S. Care Delivery volumes (same‑market treatments down 37 bps), ~EUR 181m of restructuring special items tied to up to 100 clinic exits (64 already closed), and an expected TDAPA‑related drag in H2 despite a Q1 boost.
• The company increased its annual dividend to $0.8716 (from $0.79), while analysts remain cautious—MarketBeat shows a consensus rating of "Reduce" with a $28 price target following several downgrades.

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS - Get Free Report) posted its earnings results on Tuesday. The company reported $0.53 EPS for the quarter, missing analysts' consensus estimates of $0.59 by ($0.06), Zacks reports. The firm had revenue of $5.34 billion during the quarter, compared to analysts' expectations of $5.41 billion. Fresenius Medical Care AG & Co. KGaA had a return on equity of 8.73% and a net margin of 5.03%.

Here are the key takeaways from Fresenius Medical Care AG & Co. KGaA's conference call:

• Fresenius reported solid Q1 results with organic revenue up 4%, operating income +10% (margin +70 bps to 10.1%), FME25+ delivering EUR 50m of sustainable savings, and completion of an accelerated EUR 1bn share buyback (24.8m shares, 8.5% of capital) while net leverage remained ~2.6x.
• U.S. Care Delivery volumes remained pressured (same‑market treatments down 37 bps) due to severe winter weather, insurance uncertainty after extended ACA subsidies expired, and elevated mortality; TDAPA gave a Q1 boost (~EUR 80m) but is expected to be a significant headwind in H2, and FME25+ restructuring costs (net special items ~EUR 181m) reflect up to 100 planned clinic closures (64 already exited).
• The large‑scale rollout of the 5008X/HV HDF care system is progressing rapidly (100k+ treatments and ~100 clinics converted so far), training and adoption are reported as strong, and production/supply targets for machines and consumables are on track—positioning future clinical and revenue upside for Care Enablement and Care Delivery.
• Value‑Based Care turned profitable for the second consecutive quarter with rising member months and improved savings rates; management highlighted strong outcomes (historical shared savings >$270m) and AI‑driven interventions that reduced hospitalizations by up to 15% and missed treatments by up to 26% for highest‑risk members.
• Care Enablement faces continued headwinds in China from volume‑based procurement and stricter tenders, which management says drove first‑quarter weakness and is expected to weigh on full‑year results (roughly below EUR 50m impact), prompting ongoing portfolio and go‑to‑market reassessment.

Fresenius Medical Care AG & Co. KGaA Trading Up 4.2%

Shares of NYSE FMS traded up $0.85 during midday trading on Wednesday, hitting $21.04. The company's stock had a trading volume of 1,304,998 shares, compared to its average volume of 636,098. The company has a current ratio of 1.26, a quick ratio of 0.92 and a debt-to-equity ratio of 0.40. The business's 50 day moving average is $22.77 and its two-hundred day moving average is $23.51. Fresenius Medical Care AG & Co. KGaA has a 12-month low of $20.02 and a 12-month high of $30.46. The firm has a market cap of $11.75 billion, a P/E ratio of 11.02, a price-to-earnings-growth ratio of 2.76 and a beta of 0.81.

Fresenius Medical Care AG & Co. KGaA Increases Dividend

The firm also recently declared an annual dividend, which will be paid on Monday, June 8th. Stockholders of record on Friday, May 22nd will be issued a $0.8716 dividend. The ex-dividend date is Friday, May 22nd. This is a positive change from Fresenius Medical Care AG & Co. KGaA's previous annual dividend of $0.79. This represents a dividend yield of 385.0%. Fresenius Medical Care AG & Co. KGaA's dividend payout ratio (DPR) is currently 29.84%.

Institutional Investors Weigh In On Fresenius Medical Care AG & Co. KGaA

Several hedge funds and other institutional investors have recently modified their holdings of FMS. Morgan Stanley raised its holdings in shares of Fresenius Medical Care AG & Co. KGaA by 47.2% in the fourth quarter. Morgan Stanley now owns 2,939,839 shares of the company's stock worth $70,027,000 after buying an additional 942,497 shares during the period. Bank of America Corp DE raised its holdings in shares of Fresenius Medical Care AG & Co. KGaA by 279.7% in the second quarter. Bank of America Corp DE now owns 337,316 shares of the company's stock worth $9,637,000 after buying an additional 248,477 shares during the period. Integral Health Asset Management LLC raised its holdings in shares of Fresenius Medical Care AG & Co. KGaA by 44.4% in the fourth quarter. Integral Health Asset Management LLC now owns 650,000 shares of the company's stock worth $15,483,000 after buying an additional 200,000 shares during the period. Qube Research & Technologies Ltd raised its holdings in shares of Fresenius Medical Care AG & Co. KGaA by 175.3% in the second quarter. Qube Research & Technologies Ltd now owns 199,563 shares of the company's stock worth $5,702,000 after buying an additional 127,073 shares during the period. Finally, XTX Topco Ltd raised its holdings in shares of Fresenius Medical Care AG & Co. KGaA by 743.3% in the fourth quarter. XTX Topco Ltd now owns 94,093 shares of the company's stock worth $2,241,000 after buying an additional 82,935 shares during the period. 8.37% of the stock is currently owned by hedge funds and other institutional investors.

Trending Headlines about Fresenius Medical Care AG & Co. KGaA

Here are the key news stories impacting Fresenius Medical Care AG & Co. KGaA this week:

• Positive Sentiment: Company reported operating income growth and margin expansion (adjusted margin 10.1%) plus organic revenue growth and faster U.S. rollout of its 5008X CAREsystems — management said adjusted EPS rose and confirmed the FY‑2026 outlook, which reassures investors on guidance execution. Fresenius Medical Care delivers strong operating income growth in Q1 2026 while advancing the U.S. rollout of 5008X CAREsystems at speed
• Positive Sentiment: Analysts and coverage note that margin expansion and expected savings from the FME25+ transformation are supporting operating income growth — a key reason traders bought the stock despite the quarter missing top‑line and EPS consensus. FMS Stock Rises Despite Q1 Earnings & Sales Miss, Margins Expand
• Positive Sentiment: Company updated FY‑2026 revenue guidance above street expectations (~$23.8B vs. consensus ~$22.9B), which supports a more constructive revenue trajectory for the year (EPS guidance text was incomplete in the release). (Company guidance release)
• Positive Sentiment: Investor commentary highlights the stock’s undervaluation given recent operational gains and buyback‑supported EPS improvement — a bullish narrative that can attract value investors. Fresenius Medical: The Undervaluation Is Getting Clearer
• Neutral Sentiment: Company released the Q1 results slide deck and earnings‑call presentation — useful for detail on segment performance, the U.S. clinic restructuring plan and FME25+ timing but not a market mover by itself. Fresenius Medical Care AG 2026 Q1 - Results - Earnings Call Presentation
• Negative Sentiment: Reported Q1 EPS ($0.53) and revenue ($5.34B) missed consensus (~$0.59 EPS, ~$5.41B revenue); reported net income was down due to one‑time transformation costs — these misses normally weigh on near‑term sentiment. Earnings Report & Transcript
• Negative Sentiment: Revenue fell ~6% year‑on‑year in Q1, driven by significant currency effects (weak U.S. dollar) and recent divestitures — a macro/FX headwind that can pressure reported growth metrics. Fresenius Medical Care's revenue falls in Q1 as weak dollar takes toll
• Negative Sentiment: Company posted lower net profit due to one‑off costs tied to restructuring; management has begun exiting a portion of U.S. clinics (64 of up to 100), a near‑term drag but part of longer‑term network optimization. Fresenius Medical Care Posts Lower Net Profit on One-Off Costs

Analysts Set New Price Targets

A number of research firms recently commented on FMS. The Goldman Sachs Group downgraded Fresenius Medical Care AG & Co. KGaA from a "buy" rating to a "neutral" rating in a research report on Tuesday, January 20th. Citigroup reissued a "neutral" rating on shares of Fresenius Medical Care AG & Co. KGaA in a research note on Friday, April 24th. Erste Group Bank cut Fresenius Medical Care AG & Co. KGaA from a "strong-buy" rating to a "hold" rating in a research note on Thursday, February 5th. Weiss Ratings cut Fresenius Medical Care AG & Co. KGaA from a "buy (b-)" rating to a "hold (c+)" rating in a research note on Friday, March 13th. Finally, Jefferies Financial Group cut Fresenius Medical Care AG & Co. KGaA from a "moderate sell" rating to a "strong sell" rating in a research note on Tuesday, February 24th. Six analysts have rated the stock with a Hold rating and four have given a Sell rating to the company's stock. According to data from MarketBeat, the company has a consensus rating of "Reduce" and a consensus price target of $28.00.

Fresenius Medical Care AG & Co. KGaA Company Profile

Fresenius Medical Care AG & Co KGaA is the world's largest integrated provider of products and services for individuals with renal diseases. The company's primary business activities encompass the operation of dialysis clinics and the manufacture and distribution of dialysis equipment, dialysis machines, dialyzers, consumables and related therapies. Through its global network of clinics, Fresenius Medical Care delivers comprehensive kidney care, including hemodialysis and peritoneal dialysis treatments, patient education and support services.

In its products segment, the company designs and produces dialysis machines, water treatment systems and disposables such as high‐flux dialyzers and bloodlines.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.